ITP: hematology’s Cosette from Les Misérables

Rao, V. Koneti

doi:10.1182/blood-2013-01-477729

Cited by 3 publications

(3 citation statements)

References 9 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After dexamethasone treatment, 5 patients responded and 5 achieved CR. All patients achieved either R or CR by the time treatment with eltrombopag was complete (median 5 days, range [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19]. The CR rate was 83.3%, whereas the R rate was 16.7%.…”

Section: Resultsmentioning

confidence: 99%

Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults

Gómez‐Almaguer

Herrera-Rojas

Jaime‐Pérez

et al. 2014

Blood

View full text Add to dashboard Cite

Key Points• Eltrombopag/dexamethasone is a safe and effective combination for treating newly diagnosed ITP patients.• This treatment may prove useful in achieving lasting responses without additional immunosuppression in some patients.Immune thrombocytopenia (ITP) results from platelet destruction and production suppression. Eltrombopag belongs to a new class of thrombopoietin-mimetic drugs that raise platelet counts in ITP patients. We performed a single-arm study to assess the response to a single course of dexamethasone (40 mg by mouth, days 1-4) in combination with eltrombopag (50 mg, days 5-32) in 12 adults with newly diagnosed ITP in an outpatient setting. Median follow-up was 12.5 months. After therapy (day 33), 100% of patients achieved at least ‡30 3

show abstract

Section: Resultsmentioning

confidence: 99%

Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults

Gómez‐Almaguer

Herrera-Rojas

Jaime‐Pérez

et al. 2014

Blood

View full text Add to dashboard Cite

show abstract

“…Severity of bleeding manifestations corresponds to degree of thrombocytopenia. Bleeding manifestations are more common with thrombocytopenia <30000/mm 3 . Corticosteroids are the mainstay in treatment.…”

Section: Resultsmentioning

confidence: 99%

“…In 1735, a German physician Paul Gottlieb Werlhof described ITP nearly 10 decades before Victor Hugo's published his novel Les misérables. ITP has an incidence of 6/100000, and the licensing of thrombopoietin mimetic agents has added a good paradigm to its management [3,4]. Corticosteroids and intravenous immunoglobulins were the mainstay of immediate treatment after 1950's with splenectomy for more than 100 years remains the only option with curative potential.…”

Section: Introductionmentioning

confidence: 99%

A Clinical Study of Patients With Idiopathic Thrombocytopenic Purpura

Rao

Patil

et al. 2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: Idiopathic thrombocytopenic purpura (ITP) is an immuunological disorder characterized by the production of antibodies targeted toward platelets. Corticosteroids and intravenous immunoglobulins were the mainstay of immediate treatment after 1950s with splenectomy for more than 100 years remains the only option with curative potential. The aim of this study was to analyze the incidence, age and sex distribution among adults, various modes of presentation, correlation between thrombocytopenia and bleeding manifestations, and various modalities of treatment of ITP in a tertiary care hospital in India.. Methods:A prospective study included 40 cases of ITP admitted to Kasturba Medical College Hospital, Manipal, from November 2005 to March 2007. Patients above 14 years of age admitted with thrombocytopenia in this institution were screened based on detailed clinical history, physical examination, and laboratory investigations. Results:The maximum incidence was in the 3 rd decade of life accounting for 27.5% of the patients. Male-to-female ratio was 1:1.9 with female preponderance. Females in the 3 rd decade had maximum incidence while males in the 4 th decade have maximum incidence. The majority (12, 85.71%) of male patients and 15 (57.69%) female patients developed purpura during the course of disease. The mean count was 17.8×10 Among the remaining patients, 3 (7.5%) had a relapse of symptoms within next 6 months and responded to repeat prednisolone started at 1 mg/kg. 2 (5%) patients were given steroids tapering dose with IV immune globulins for initial 5 days as therapy to which they responded. Conclusion:Idiopathic thrombocytopenia is 1.9 times more common in females than males. Most common presentation is bleeding spots over body. Bleeding manifestations are more common with thrombocytopenia <30000/mm 3 . Corticosteroids are the mainstay in treatment. Complete remission is seen in up to 57.5% of the patients. Splenectomy is the second modality of treatment in ITP. Complete and sustained remission is seen 75% of patients.

show abstract